for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lupin Limited

LUPN.NS

Latest Trade

905.95INR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

504.75

 - 

919.20

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Latest Developments

Lupin Launches Generic Version Of Apriso

May 19 (Reuters) - Lupin Ltd <LUPN.NS>::LUPIN LAUNCHES AUTHORIZED GENERIC VERSION OF APRISO.

Lupin Says Positive Topline Results From Phase 3 Study Of Single-Dose Solosec For Treatment Of Trichomoniasis

May 4 (Reuters) - Lupin Ltd <LUPN.NS>::LUPIN LTD SAYS POSITIVE TOPLINE RESULTS FROM ITS PHASE 3 STUDY OF SINGLE-DOSE SOLOSEC (SECNIDAZOLE) FOR TREATMENT OF TRICHOMONIASIS..LUPIN LTD SAYS PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN PHASE 3 CLINICAL TRIAL OF 147 PATIENTS.LUPIN LTD SAYS SOLOSEC 2G ORAL GRANULES WAS GENERALLY WELL-TOLERATED AMONG STUDY SUBJECTS.LUPIN LTD SAYS PLANS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION FOR SOLOSEC® TO THE U.S. FDA FOR THE TREATMENT OF TRICHOMONIASIS IN H2 2020.

Lupin Announces Positive Topline Results From Study Of Single-Dose Solosec® For Treatment Of Trichomoniasis

May 4 (Reuters) - Lupin Ltd <LUPN.NS>::LUPIN ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE 3 STUDY OF SINGLE-DOSE SOLOSEC® (SECNIDAZOLE) FOR THE TREATMENT OF TRICHOMONIASIS.LUPIN PHARMACEUTICALS - PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN PHASE 3 CLINICAL TRIAL OF SINGLE-DOSE SOLOSEC OF 147 PATIENTS.LUPIN PHARMACEUTICALS - PLANS TO SUBMIT SUPPLEMENTAL NDA FOR SOLOSEC TO FDA FOR TREATMENT OF TRICHOMONIASIS IN H2 2020.

Lupin -Gets Tentative USFDA Approval For Arformoterol Tartrate Inhalation Solution 15 Mcg (Base)/2 Ml

April 29 (Reuters) - Lupin Ltd <LUPN.NS>::LUPIN LTD -RECEIVES TENTATIVE APPROVAL FOR ARFORMOTEROL TARTRATE INHALATION SOLUTION 15 MCG (BASE)/2 ML.

Lupin Says SOLOSEC Achieves Preferred Status On Express Scripts National Preferred Formulary

April 22 (Reuters) - Lupin Ltd <LUPN.NS>::LUPIN ANNOUNCES SOLOSEC ACHIEVEMENT OF PREFERRED STATUS ON EXPRESS SCRIPTS NATIONAL PREFERRED FORMULARY.

Lupin's Mandideep Unit II Facility Gets EIR From U.S. FDA.

April 15 (Reuters) - Lupin Ltd <LUPN.NS>::LUPIN'S MANDIDEEP UNIT II FACILITY RECEIVES EIR FROM U.S. FDA..

Lupin Ltd - Announces Launch Of Mycophenolic Acid Delayed-Release Tablets Usp, 180 Mg And 360 Mg

Lupin Ltd <LUPN.NS>::LUPIN LTD - ANNOUNCES LAUNCH OF MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS USP, 180 MG AND 360 MG.

India's Lupin Launches Betamethasone Dipropionate Ointment USP (Augmented)

March 20 (Reuters) - Lupin Ltd <LUPN.NS>::LAUNCHES BETAMETHASONE DIPROPIONATE OINTMENT USP (AUGMENTED).

India's Lupin Launches Generic Version Of Horizon Therapeutics' Arthritis Drug Vimovo

March 5 (Reuters) - Lupin Ltd <LUPN.NS>::LAUNCHES AUTHORIZED GENERIC VERSION OF VIMOVO.LAUNCHES AUTHORIZED GENERIC FOR HORIZON THERAPEUTICS' VIMOVO DELAYED RELEASE TABLETS IN U.S..

India's Lupin Launches Moxifloxacin Ophthalmic Solution USP 0.5%

Feb 14 (Reuters) - Lupin Ltd <LUPN.NS>::INDIA'S LUPIN LTD SAYS LAUNCHES MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5%.PRODUCT TO BE MANUFACTURED AT CO'S PITHAMPUR (UNIT-II) FACILITY, INDIA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up